Reviva to Present New Brilaroxazine Data at ASPET 2024
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a company in the late stages of developing treatments for unmet medical needs primarily targeting the central nervous system, inflammatory, and cardiometabolic diseases, recently announced an upcoming presentation of new pharmacology data on its drug candidate brilaroxazine. The presentation will be made by the company's Founder, President, and CEO, Dr. Laxminarayan Bhat, at the ASPET 2024 Annual Meeting in Arlington, VA, from May 16 to 19, 2024.
The presentation will be divided into two poster sessions. The first poster, titled "Brilaroxazine Displays Limited Interaction with Clinically Relevant Drug Transporters," will be displayed on Poster Board 806, Abstract Number 129049, in Room Independence AB on May 19, 2024, from 5:15 to 7:15 pm ET. The second poster, "Absorption, Metabolism, and Excretion of Brilaroxazine in Rats," will be displayed on Poster Board 807, Abstract Number 129061, in the same room and during the same time slot.
Brilaroxazine is an innovative chemical entity developed in-house by Reviva Pharmaceuticals. It shows strong affinity and selectivity for key serotonin and dopamine receptors involved in schizophrenia and its associated symptoms. The global Phase 3 RECOVER trial in schizophrenia revealed that brilaroxazine successfully met all primary and secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in major symptom domains at week 4 with a 50 mg dose, compared to a placebo. The drug exhibited a generally well-tolerated side effect profile, with lower discontinuation rates than the placebo group.
Moreover, findings from a clinical drug-drug interaction (DDI) study indicated that CYP3A4 inhibitors do not have a clinically significant impact on brilaroxazine. Reviva believes it has completed a full set of regulatory-compliant toxicology and safety pharmacology studies for brilaroxazine. The company plans to develop brilaroxazine for other neuropsychiatric conditions, such as bipolar disorder, major depressive disorder (MDD), and attention-deficit/hyperactivity disorder (ADHD).
Additionally, brilaroxazine has shown promising activity in preclinical studies for inflammatory diseases like psoriasis, pulmonary arterial hypertension (PAH), and idiopathic pulmonary fibrosis (IPF). It has demonstrated the ability to mitigate fibrosis and inflammation in animal models, and has already received Orphan Drug Designation from the U.S. FDA for PAH and IPF.
Reviva Pharmaceuticals is dedicated to discovering, developing, and commercializing next-generation therapeutics aimed at addressing unmet medical needs and reducing the societal and personal burdens of various diseases. The company's current pipeline includes brilaroxazine (RP5063) and another drug candidate, RP1208, both of which are new chemical entities discovered internally. Reviva holds composition of matter patents for both candidates in the United States, Europe, and several other countries.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
